MerckMEX:MRK 74 PS Ratio is 4.69 as of Jul. 09, 2026, which is 6% above its 10-year median of 4.41. GuruFocus rates MEX:MRK with a GF Score™ of 74/100 and a GF Value™ of MXN2,129.90 (Fairly Valued). The stock has 7 warning signs investors should review. Among 952 Drug Manufacturers companies, Merck ranks worse than 73.74% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Merck's share price is MXN2263.00.
Merck's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN482.88. Hence, Merck's PS Ratio for today is 4.69.
Warning Sign:
Merck & Co Inc stock PS Ratio (=4.77) is close to 2-year high of 5.2.
The historical rank and industry rank for Merck's PS Ratio or its related term are showing as below:
MEX:MRK'
s PS Ratio Range Over the Past 10 Years
Min: 3.02 Med: 4.41 Max: 5.75
Current: 4.77
During the past 13 years, Merck's highest PS Ratio was 5.75. The lowest was 3.02. And the median was 4.41.
MEX:MRK's PS Ratio is ranked worse than 73.74% of 952
companies
in the Drug Manufacturers industry
Industry Median: 2.265
vs MEX:MRK: 4.77
Merck's Revenue per Sharefor the
three
months ended in Mar. 2026 was MXN118.80.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN482.88.
During the past 12 months, the average Revenue per Share Growth Rate of Merck was 4.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 3.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 9.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 7.40% per year.
During the past 13 years, Merck's highest 3-Year average Revenue per Share Growth Rate was 22.80% per year. The lowest was -16.50% per year. And the median was 6.70% per year.
Back to Basics: PS Ratio
Merck (MEX:MRK) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Merck PS Ratio Related Terms
Merck PS Ratio Historical Data
* Premium members only.
The historical data trend for Merck's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Merck's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merck PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Merck's PS Ratio distribution charts can be found below:
* The bar in red indicates where Merck's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Merck's Share Price of today is MXN2263.00. Merck's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN482.88.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Merck (MEX:MRK) has a PS Ratio of 4.69 as of Jul. 09, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Merck and its competitors. This is near median its historical median of 4.41. Over the past decade, Merck's PS Ratio has ranged from 3.02 to 5.75. According to the industry distribution chart, Merck ranks #702 out of 952 companies in the Drug Manufacturers industry, placing it in the top 73.7%.
Is Merck's PS Ratio too high?
Merck's current PS Ratio of 4.69 is near median its 10-year median of 4.41. Over the past 10 years, this metric has ranged from a low of 3.02 to a high of 5.75. The Drug Manufacturers industry median PS Ratio is 2.27. Merck's value of 4.69 is 107.1% above this industry median. Based on the distribution chart, Merck ranks #702 out of 952 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Merck has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck's PS Ratio compare to AMGN and ABBV?
According to the Drug Manufacturers industry distribution chart, Merck ranks #702 out of 952 companies for PS Ratio. This places Merck in the lower half of its industry. The industry median PS Ratio is 2.27. Merck's value of 4.69 is 107.1% above this benchmark. Historically, Merck's own PS Ratio has ranged from 3.02 to 5.75 over the past decade. While the company's 10-year median is 4.41 vs. the industry median of 2.27, Merck has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.27, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Merck's current PS Ratio of 4.69 is 107.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Merck and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Merck's current PS Ratio is 4.69, which is near median its own 10-year median of 4.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Based on GuruFocus' analysis, Merck (MEX:MRK) is currently considered Fairly Valued. The stock's GF Value™ is MXN2,129.90, compared to a current price of MXN2,263.00 — trading 6.2% above its estimated fair value. The current PS Ratio is 4.69, which is near median its 10-year median of 4.41 and 107.1% above the Drug Manufacturers industry median of 2.27. Merck's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Merck (MEX:MRK), the current PS Ratio is 4.69 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Merck (MEX:MRK) Overvalued in 2026?
Based on GuruFocus' analysis, Merck stock appears to be overvalued.
The current stock price of MXN2,263.00 is trading 6.2% above its estimated GF Value™ of MXN2,129.90.
GuruFocus considers Merck to be Fairly Valued.
Key valuation signals for MEX:MRK:
PS Ratio: 4.69 (near median its 10-year median of 4.41)
GF Value™: MXN2,129.90 vs. price of MXN2,263.00 (6.2% above fair value)
Industry Position: 107.1% above the Drug Manufacturers median (#702 of 952)
No single metric tells the full story. See the MEX:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
74GF Score
Get the complete analysis for MEX:MRK
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MRK has been successfully added to your 
